MedPath

Memantine

Generic Name
Memantine
Brand Names
Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
Drug Type
Small Molecule
Chemical Formula
C12H21N
CAS Number
19982-08-2
Unique Ingredient Identifier
W8O17SJF3T
Background

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease .

In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 . In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 .

Indication

Memantine is used to manage moderate to severe Alzheimer's dementia .

A more recent systemic review and meta-analysis indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia .

Associated Conditions
Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Memantine
Drug: Placebo
First Posted Date
2007-05-21
Last Posted Date
2014-08-11
Lead Sponsor
Florida Atlantic University
Target Recruit Count
60
Registration Number
NCT00476008
Locations
🇺🇸

Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: placebo
Drug: Memantine
First Posted Date
2007-05-04
Last Posted Date
2009-12-24
Lead Sponsor
Forest Laboratories
Target Recruit Count
265
Registration Number
NCT00469456
Locations
🇿🇦

Forest Investigative Site, Cape Town, W. Cape, South Africa

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

Phase 4
Terminated
Conditions
Traumatic Brain Injury
Interventions
Drug: Placebo
Drug: Memantine
First Posted Date
2007-04-18
Last Posted Date
2017-01-23
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
11
Registration Number
NCT00462228
Locations
🇺🇸

University of Missouri-Columbia, Columbia,, Missouri, United States

A Pilot Clinical Trial Of Memantine for Essential Tremor

Phase 4
Completed
Conditions
Essential Tremor
Interventions
First Posted Date
2007-02-26
Last Posted Date
2012-06-22
Lead Sponsor
VA Greater Los Angeles Healthcare System
Target Recruit Count
16
Registration Number
NCT00439699
Locations
🇺🇸

VA Greater Los Angeles, Los Angeles, California, United States

The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2006-12-11
Last Posted Date
2011-03-02
Lead Sponsor
University of Alberta
Target Recruit Count
42
Registration Number
NCT00409721
Locations
🇨🇦

Calgary ALS Neuromuscular Clinic, Calgary, Alberta, Canada

🇨🇦

University of Alberta ALS Clinic, Edmonton, Alberta, Canada

Memantine for Agitation and Aggression in Severe Alzheimer's Disease

Phase 4
Completed
Conditions
Alzheimer's Disease
First Posted Date
2006-11-17
Last Posted Date
2024-01-31
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
31
Registration Number
NCT00401167
Locations
🇨🇦

North York General Hospital, Toronto, Ontario, Canada

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Memantine for Agitation in Dementia

Phase 4
Completed
Conditions
DEMENTIA
First Posted Date
2006-09-01
Last Posted Date
2022-04-06
Lead Sponsor
East Kent Hospitals University NHS Foundation Trust
Target Recruit Count
153
Registration Number
NCT00371059
Locations
🇬🇧

Oxleas Nhs Foundation Trust, Dartford, Kent, United Kingdom

🇬🇧

Kent and Medway NHS and Social Care Partnership Trust, Folkestone, Kent, United Kingdom

Memantine Augmentation of Antidepressants

Phase 4
Completed
Conditions
Depressive Disorder
Interventions
Drug: Placebo
Drug: memantine
First Posted Date
2006-06-27
Last Posted Date
2018-07-11
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
31
Registration Number
NCT00344682
Locations
🇺🇸

Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School), Worcester, Massachusetts, United States

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

Phase 4
Completed
Conditions
Alzheimer's Disease
First Posted Date
2006-06-08
Last Posted Date
2008-01-07
Lead Sponsor
Forest Laboratories
Target Recruit Count
75
Registration Number
NCT00334906
Locations
🇺🇸

Forest Laboratories, Jersey City, New Jersey, United States

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

Phase 4
Completed
Conditions
Binge Eating Disorder
First Posted Date
2006-05-29
Last Posted Date
2007-08-14
Lead Sponsor
Mclean Hospital
Target Recruit Count
15
Registration Number
NCT00330655
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath